Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 11, 2009, Pages 1366-1375

  Gagne, Katia ^a,b,m   Bussson, Marc ^c   Bignon, Jean Denis ^a,b   Balère Appert, Maria Lorraine ^d   Loiseau, Pascale ^e   Dormoy, Anne ^f   Dubois, Valérie ^g   Perrier, Pascale ^h   Jollet, Isabelle ⁱ   Bois, Monique ⁱ   Masson, Dominique ^j   Moine, Agnès ^j   Absi, Léna ^k   Blaise, Didier ^l   Charron, Dominique ^c,e   Raffoux, Colette ^d  

^a UNIVERSITÉ DE NANTES   (France)

^b Laboratoire HLA   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d France Greffe de Moelle   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f Laboratoire HLA   (France)

^g Laboratoire HLA   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ Laboratoire HLA   (France)

^j Laboratoire HLA   (France)

^k Laboratoire HLA   (France)

^l SFGM TC   (France)

^m ETABLISSEMENT FRANÇAIS DU SANG   (France)

more..

Author keywords

Graft versus host disease; HLA Bw4; Killer immunoglobulin like receptors; KIR genotypes; KIR ligands; KIR3DL1; KIR3DS1; Relapse; Survival; Unrelated hematopoietic stem cell transplantation

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOIMMUNITY; ARTICLE; CHILD; DONOR; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RELAPSE; RISK ASSESSMENT;

EID: 70350600942     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.06.015     Document Type: Article

References (48)

1. Hansen JA, Petersdorf EW, Lin MT, et al. Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes. Immunol Res. 2008;41:56-78.
2. Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol. 2008;142:877-888.
3. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
4. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503-510.
5. Parham PMHC. class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5:201-214.
6. Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A. Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood. 2008;112:708-710.
7. Stewart CA, Laugier-Anfossi F, Vely F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA. 2005;102: 13224-13229.
8. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol. 2007;179: 854-868.
9. Morvan M, David G, Sebille V, et al. HLA KIR ligand environments and activating KIR control KIR NK-cell functions. Eur J Immunol. 2008;38:3474-3486.
10. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol. 2007; 178:235-241.
11. Gillespie GM, Bashirova A, Dong T, McVicar DW, Rowland-Jones SL, Carrington M. Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8 + T cell epitopes. AIDS Res Hum Retroviruses. 2007;23:451-455.
12. Middleton D, Williams F, Halfpenny IA. KIR genes. Transpl Immunol. 2005;14:135-142.
13. Single RM, Martin MP, Meyer D, Gao X, Carrington M. Methods for assessing gene content diversity of KIR with examples from a global set of populations. Immunogenetics. 2008;60:711-725.
14. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753-763.
15. Robinson J, Waller MJ, Fail SC, Marsh SG. The IMGT/HLA and IPD databases. Hum Mutat. 2006;27:1192-1199.
16. Ruggeri L, Mancusi A, Burchielli E, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2008;40:84-90.
17. Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009;23:492-500.
18. Bignon JD, Gagne K. KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol. 2005;17:553-559.
19. Witt CS, Christiansen FT. The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang. 2006;90:10-20.
20. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878-4884.
21. Gagne K, Brizard G, Gueglio B, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol. 2002;63:271-280.
22. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172: 644-650.
23. Shilling HG, Young N, Guethlein LA, et al. Genetic control of human NK cell repertoire. J Immunol. 2002;169:239-247.
24. Yokoyama WM, Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev. 2006; 214:143-154.
25. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood. 2008;112:2369-2380.
26. Kim S, Sunwoo JB, Yang L, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA. 2008;105:3053-3058.
27. Gagne K, Busson M, Balere-Appert ML, et al. Relevance of KIR gene matching in unrelated hematopoietic stem cell transplantations. Tissue Antigens. 2007;69(Suppl 1):118-122.
28. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
29. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
30. Loiseau P, Busson M, Balere ML, et al. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant. 2007;13:965-974.
31. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. JASA. 1999;94:496.
32. Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972;34:187-220.
33. Cook MA, Milligan DW, Fegan CD, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004;103:1521-1526.
34. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109:5058-5061.
35. Sun JY, Gaidulis L, Dagis A, et al. Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant. 2005;36:525-530.
36. De Santis D, Bishara A, Witt CS, et al. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens. 2005;65:519-528.
37. Kroger N, Binder T, Zabelina T, et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation. 2006;82:1024-1030.
38. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814-819.
39. Yabe T, Matsuo K, Hirayasu K, et al. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant. 2008;14:75-87.
40. Schellekens J, Rozemuller EH, Petersen EJ, van den Tweel JG, Verdonck LF, Tilanus MG. Patients benefit from the addition of KIR repertoire data to the donor selection procedure for unrelated haematopoietic stem cell transplantation. Mol Immunol. 2008;45:981-989.
41. Kim SY, Choi HB, Yoon HY, et al. Influence of killer cell immunoglobulin-like receptor genotypes on acute graft-vs-host disease after unrelated hematopoietic stem cell transplantation in Koreans. Tissue Antigens. 2007;69(Suppl 1):114-117.
42. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113:726-732.
43. La Nasa G, Littera R, Locatelli F, et al. Status of donor-recipient HLA class I ligands and not the KIR genotype is predictive for the outcome of unrelated hematopoietic stem cell transplantation in beta-thalassemia patients. Biol Blood Marrow Transplant. 2007;13:1358-1368.
44. Ludajic K, Balavarca Y, Bickeboller H, et al. KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation. Bone Marrow Transplant. 2009;44:97-103.
45. Foley BA, De Santis D, Van Beelen E, Lathbury LJ, Christiansen FT, Witt CS. The reactivity of Bw4 + HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood. 2008;112:435-443.
46. Gardiner CM, Guethlein LA, Shilling HG, et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol. 2001;166:2992-3001.
47. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol. 2005; 175:5222-5229.
48. Morvan M, Willem C, Gagne K, et al. Phenotypic and functional analyses of KIR3DL1+ and KIR3DS1 + NK cell subsets demonstrate differential regulation by Bw4 molecules and induced KIR3DS1 expression on stimulated NK cells. J Immunol. 2009; 182:6727-6735.